title: Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer.
abstract: TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
authors.affiliation: Molecular OncoSurgery Group; University of Heidelberg and German Cancer Research Center; Heidelberg, Germany.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Herr
authors.forename: Ariane
authors.initials: A
authors.lastname: Groth
authors.forename: Alexei V
authors.initials: AV
authors.lastname: Salnikov
authors.forename: Markus W
authors.initials: MW
authors.lastname: Büchler
authors.forename: Gerhard
authors.initials: G
authors.lastname: Moldenhauer